Navigation Links
Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
Date:5/6/2008

ialization and partnering.

Conference Call Details

To participate in today's live 5 PM ET/2 PM PT call by telephone, please dial 877-440-5791 from the U.S. or +1-719-325-4909 for international callers. In addition, the live conference call is being webcast and can be accessed on the "Events" page of the "News & Events" section of the Company's website at http://www.poniard.com. A replay of the webcast will be available on the Company's website for 14 days.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum therapy with an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and hormone-refractory prostate cancers, as well as a Phase 1 clinical trial of oral picoplatin in solid tumors. Picoplatin has not been approved by any regulatory authority for use in humans. For additional information please visit http://www.poniard.com.

Poniard Pharmaceuticals, Inc.

Condensed Consolidated Statements of Operations

(In thousands, except per share data)

(Unaudited)

Three Months Ended March 31,

2008 2007

Revenues
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Poniard Pharmaceuticals Announces Upcoming Conference Participation
2. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
3. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
5. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
6. Onyx Pharmaceuticals Reports 2008 First Quarter Results
7. SGX Pharmaceuticals Schedules Teleconference and Webcast to Discuss First Quarter 2008 Results and Provide Pipeline Update
8. Israels Prestigious Presidents Conference to Feature Oramed Pharmaceuticals Revolutionary Oral Insulin Capsule
9. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
10. Keryx Biopharmaceuticals to Present at the Deutsche Bank 33rd Annual Health Care Conference
11. GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Sept. 2, 2014  Technology Applications International Corporation (the ... wholly-owned subsidiary Renuell Int,l, Inc. has signed an additional ... Administration ("NASA") at the Johnson Space Center in ... photos: tapplic.com/houstonphotos/ Charles ... pleased to announce our latest, exclusive agreement with NASA. ...
(Date:9/2/2014)...  Xencor, Inc. (NASDAQ: XNCR ), ... for the treatment of autoimmune diseases, asthma and ... of Debra Zack , M.D., Ph.D., vice ... Lloyd Rowland , senior vice president, chief compliance ... expertise in biologics clinical development and medical affairs ...
(Date:9/2/2014)... Rocky Mount, NC (PRWEB) September 02, 2014 ... the establishment of its 11th clinical research site: PMG ... has assumed ownership and operation of the clinical research ... NC, further expanding PMG’s presence in eastern North Carolina. ... 130,000 patients. For the patients in Rocky Mount and ...
(Date:9/1/2014)... Sept. 1, 2014 Reportlinker.com announces that ... its catalogue: India Solid Waste Management ... http://www.reportlinker.com/p02350445/India-Solid-Waste-Management-Vehicles-Market-Forecast-and-Opportunities-2019.html In ... main governing bodies responsible for complete handling and ... an average, around 135,000 MT solid waste is ...
Breaking Biology Technology:Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 2Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 3Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 3PMG Research Announces the Formation of its Eleventh Site 2PMG Research Announces the Formation of its Eleventh Site 3India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 2India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 3India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 4India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 5India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 6India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 7India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 8
... The Muscular Dystrophy Association announced today that it ... biotechnology company, to develop and test a "dissociative glucocorticoid" ... (DMD) . (Logo: http://photos.prnewswire.com/prnh/20120424/DC93207LOGO ) ... Institutes of Health Therapeutics for Rare and Neglected Diseases ...
... May 3, 2012 ZyGEM Corp. Ltd., a developer ... DNA and other nucleic acids, today announced it has ... distribution of ZyGEM,s DNA and RNA extraction products in ... a leading provider of quantitative real-time PCR (qPCR) services ...
... SEATTLE, May 3, 2012 CMC Biologics, a leading ... technical excellence in process development and cGMP manufacture ... Manufacturing Company of the Year – Large Category.   The ... partnership with Impact Washington, brought together nearly 300 leaders ...
Cached Biology Technology:MDA Supports Development of 'Dissociative Glucocorticoid' for DMD 2MDA Supports Development of 'Dissociative Glucocorticoid' for DMD 3ZyGEM Teams With TATAA Biocenter To Distribute Its Innovative Nucleic acid Extraction Kits 2ZyGEM Teams With TATAA Biocenter To Distribute Its Innovative Nucleic acid Extraction Kits 3CMC Biologics Honored as Finalist for Washington's Manufacturing Company of the Year Award 2
(Date:9/2/2014)... losing weight is enough to prevent Type 2 diabetes, don,t ... 2014 issue of The FASEB Journal , ... Type 2 diabetes. This study compared genetically identical twins-one heavier ... the circulating metabolites, including those related to Type 2 diabetes, ... These findings suggest that the onset of this type of ...
(Date:9/2/2014)... birds, also known as perching birds, that migrate by ... do in autumn to reach their destinations. This seasonal ... that only make short migratory flights, says researcher Cecilia ... Behavioral Ecology and Sociobiology . , Nilsson, ... a tracking radar to measure over three years the ...
(Date:9/2/2014)... the last decade in Taiyuan, China, have substantially improved ... greater than 50% reduction in costs associated with loss ... to researchers at the Columbia Center for Children,s Environmental ... the Shanxi Medical University, the Center of Diseases Control ... School of Public Health. , The study is the ...
Breaking Biology News(10 mins):What you eat and not just the number of calories, is a significant factor in diabetes risk 2Migrating birds sprint in spring, but take things easy in autumn 2Clean air halves health costs in Chinese city 2
... at least 20 percent of adults in the United ... that prevents bones from rubbing together. By studying the ... how the earliest stages of arthritis make the tissue ... running or jumping. The findings could help researchers ...
... ARBOR, Mich. For nearly two years, University of Michigan ... clinical trial of stem cell injections in patients with the ... ALS or Lou Gehrig,s disease. Now, a new ... way for U-M to become the second site in the ...
... sometimes called "hardening of the arteries" is ... countries. A cell-permeable peptide containing the NF-ĸB nuclear localization ... controlling the development of atherosclerotic disease. This study is ... American Journal of Pathology . Atherosclerosis is a ...
Cached Biology News:Hop, skip or jump? Study says no to all of the above 2Hop, skip or jump? Study says no to all of the above 3FDA approves Phase II of stem cell trial for ALS led by U-M's Dr. Eva Feldman 2Cell-permeable peptide shows promise for controlling cardiovascular disease 2
... The Fujifilm Life Science FLA-8000 Fluorescent Image ... in a single laser imaging system. This ... samples labeled with fluorescent dyes or radioisotopes ... most demanding laboratories. Speed, image quality and ...
...
...
... PC, is used to perform runs ... from the Experion automated electrophoresis system. ... and simulated gel views and summarizes ... a Results table. This software is ...
Biology Products: